Skip to main content
Fig. 7 | Alzheimer's Research & Therapy

Fig. 7

From: Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer’s disease and frontotemporal dementia

Fig. 7

Active immunotherapy by tau294–305 epitope to hepatitis B core immunodominant region (T294-HBc) virus-like particle (VLP) vaccine reduced microgliosis in Tau.P301S mice. Microgliosis in brain of mice treated with or without vaccine and of wild-type (WT) mice was detected by IHC and Western blotting with anti-ionized calcium-binding adaptor molecule-1 (anti-Iba-1) antibody. Microgliosis in the brain (a), cortex (b), and hippocampal CA1 (c) and dentate gyrus (DG) regions (d) was quantified by morphometric analysis. e Iba-1 levels detected by Western blot analysis. The Western blotting signals were quantified using IPwin5 Image-Pro Plus software, and GAPDH was used as a control. Scale bar is 200 μm (compared with adjuvant-treated mice; **P < 0.01, Student’s t test)

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193